Home » Stocks » SRNE

Sorrento Therapeutics, Inc. (SRNE)

Stock Price: $10.97 USD -0.04 (-0.32%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
Market Cap 3.04B
Revenue (ttm) 39.99M
Net Income (ttm) -298.46M
Shares Out 229.82M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE 1.18
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $10.97
Previous Close $11.01
Change ($) -0.04
Change (%) -0.32%
Day's Open 11.08
Day's Range 10.73 - 11.40
Day's Volume 10,825,976
52-Week Range 1.55 - 19.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 10 hours ago

Sorrento Therapeutics (SRNE) closed at $10.97 in the latest trading session, marking a -0.32% move from the prior day.

Zacks Investment Research - 2 days ago

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 3 days ago

The biotech certainly has plenty of COVID-19 candidates in the hopper.

FreightWaves - 5 days ago

UPS Airlines pilots are testing themselves for COVID midflight, using a novel rapid antigen device that has yet to be approved by the U.S., and sending the results ahead to Hong Kong in an eff...

Other stocks mentioned: UPS
Zacks Investment Research - 1 week ago

In the latest trading session, Sorrento Therapeutics (SRNE) closed at $13.98, marking a -0.71% move from the previous day.

Zacks Investment Research - 1 week ago

Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.

The Motley Fool - 1 week ago

Investors should be cautious until the biotech has data from a controlled study.

The Motley Fool - 1 week ago

These biotech companies may be among the winners of the coronavirus treatment race -- if all goes well in clinical trials.

Other stocks mentioned: GME, GSK, LLY, MRNA, VIR
GlobeNewsWire - 2 weeks ago

SAN DIEGO, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the formation of ADNAB, Inc., a subsidiary Company, that will develop and co...

The Motley Fool - 3 weeks ago

The biotech announced promising results for its experimental coronavirus therapy.

GlobeNewsWire - 3 weeks ago

SAN DIEGO, Jan. 31, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today additional positive results from its Phase 1b study of human allogeneic adip...

The Motley Fool - 3 weeks ago

The company has several promising treatments in its pipeline.

24/7 Wall Street - 3 weeks ago

With the trading day practically over, the broad markets were sliding into the weekend.

Other stocks mentioned: BIIB, DDD, DUK, F, AKBA, HOG, LXRX, MTN, PHM
The Motley Fool - 4 weeks ago

The biotech reported encouraging early results for one of its experimental COVID-19 therapies.

GlobeNewsWire - 4 weeks ago

SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today positive preliminary results from its Phase 1b study of human allogeneic adi...

Forbes - 1 month ago

Sorrento Therapeutics stock, a clinical stage biopharma company that develops treatments for cancer and neurodegenerative diseases among others, has rallied by a solid 42% over the last 10 tra...

The Motley Fool - 1 month ago

Can this biotech finally demonstrate progress in its COVID-19 pipeline before it's too late?

Seeking Alpha - 1 month ago

Sorrento Therapeutics, Inc. (SRNE) CEO Henry Ji Presents at B. Riley Virtual Oncology Conference (Transcript)

The Motley Fool - 1 month ago

The biotech announced the presentation of encouraging data for its experimental COVID-19 antibody therapy STI-2020.

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutatio...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upco...

The Motley Fool - 1 month ago

Success tends to bring more success.

Other stocks mentioned: BNGO
GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upco...

Zacks Investment Research - 1 month ago

Sorrento Therapeutics (SRNE) closed the most recent trading day at $7.03, moving -0.57% from the previous trading session.

GlobeNewsWire - 1 month ago

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that a Marketing Authorization Application has been submitted by its agents ...

CNBC - 2 months ago

Sorrento Therapeutics is developing an antibodies injection and nose drops to fight Covid-19 and its variant strains.

GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that an Emergency Use Authorization (EUA) Application has been submitted to ...

InvestorPlace - 2 months ago

Nearly a third of SRNE stock's float has been sold short. This sets up a catalyst for a short-term move, but avoid a long-term investment.

InvestorPlace - 2 months ago

Sorrento just received a grant of up to $34 million from Washington, while multiple institutions own meaningful amounts of SRNE stock. The post Government and Institutional Support Are Positiv...

The Motley Fool - 2 months ago

The new version is more potent, and therefore requires a lower dose.

Benzinga - 2 months ago

Sorrento Therapeutics (NASDAQ: SRNE) shares are trading higher on Wednesday after the company announced it has received CLIA Licensure from the State of California that permits testing of clin...

Other stocks mentioned: INFI
InvestorPlace - 2 months ago

Sorrento Therapeutics is poised to roll out clinical testing trials in California. SRNE stock is up in pre-market trading on Wednesday as the country continues to post record Covid-19 diagnose...

GlobeNewsWire - 2 months ago

- RT-PCR Emergency Use Authorization (EUA)-approved test using nasal pharyngeal swab

InvestorPlace - 2 months ago

Sorrento Therapeutics has seen SRNE stock close between $5.76 and $8.20 in the past month. Here's why it's time for investors to be careful.

InvestorPlace - 2 months ago

SRNE stock fell out of favor as bigger vaccine developers grabbed the headlines but that may change soon. The post Covid-19 Vaccine Makers Still Make Sense, Including Sorrento Therapeutics app...

InvestorPlace - 2 months ago

SRNE stock may be bouncing back, but given its grab bag of issues, skip out on this fading coronavirus play. The post Don't Chase the Rebound in Sorrento — It's Not Worth the Risk appeared fir...

InvestorPlace - 2 months ago

Sorrento Therapeutics was an early pandemic winner. But as the world closes in on multiple vaccines, SRNE stock looks to be too late.

InvestorPlace - 2 months ago

Investors seeking a longshot coronavirus play continue to eye SRNE stock despite Sorrento Therapeutics' high risk and continued volatility. The post Hopefuls Back Sorrento Therapeutics But Tim...

InvestorPlace - 2 months ago

The Covid-19 race is close to ending. It seems unlikely that Sorrento stock can pull a rabbit out of a hat with the frontrunners emerging.

InvestorPlace - 2 months ago

Thanks to Sorrento Therapeutics' all-out pivot to address the Covid-19 pandemic, SRNE stock initially became one of the most popular investments. But as both the vaccine and treatment race tig...

InvestorPlace - 2 months ago

SRNE stock has tumbled as larger players have shown progress toward a vaccine. But this isn't just a vaccine play, and the story is far from over.

InvestorPlace - 2 months ago

Avoid Sorrento Therapeutics which is still burning cash with no end in sight. SRNE stock will become more diluted as the company consistently raises cash.

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Pi...

The Motley Fool - 2 months ago

The Nasdaq Composite pushed further into all-time high territory Friday morning.

Other stocks mentioned: NVAX, MRNA
Benzinga - 2 months ago

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares, which have been given to much volatility, are rallying sharply Friday. What Happened: SmartPharm Therapeutics, a subsidiary of Sorrento, announ...

The Motley Fool - 2 months ago

The biotech's COVID-19 pipeline lands a major vote of confidence.

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 27, 2020 (GLOBE NEWSWIRE) -- SmartPharm Therapeutics, Inc. (“SmartPharm”), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and developer of...

InvestorPlace - 3 months ago

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here's how this affects other Covid-19-related biotech stocks. The post 7 Biotech Stocks That Are Locked in the Race ...

Other stocks mentioned: ABT, AZN, GILD, INO, JNJ, NVAX, REGN
InvestorPlace - 3 months ago

In this competition, Sorrento is a different beast because it's not just working on a vaccine, it's working on Covid-19 testing, neutralizing antibodies and preventive “shields,” among other p...

About SRNE

Sorrento Therapeutics, a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a dru... [Read more...]

Industry
Biotechnology
Founded
2006
CEO
Henry Ji
Employees
310
Stock Exchange
NASDAQ
Ticker Symbol
SRNE
Full Company Profile

Financial Performance

In 2020, SRNE's revenue was $39.99 million, an increase of 27.21% compared to the previous year's $31.43 million. Losses were -$298.46 million, 2.19% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for SRNE stock is "Strong Buy." The 12-month stock price forecast is 28.00, which is an increase of 155.24% from the latest price.

Price Target
$28.00
(155.24% upside)
Analyst Consensus: Strong Buy